Emerging treatment options for refractory immune thrombocytopenia

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses emerging treatment options for refractory immune thrombocytopenia (ITP). For those patients who do not respond to all current treatment options, there are several new therapies in development. The Fc receptor inhibitor efgartigimod has been efficacious in IV formulations, and the BTK inhibitor rilzabrutinib is expected to produce positive results following the completion of the Phase III LUNA3 trial (NCT04562766). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.